Regulatory & legal
Bioeconomy trade disputes at the WTO
How the SPS Agreement turns a trade dispute into a question about evidence, what the case law counts as sufficient scientific evidence, and why the WTO has never ruled on whether a GM crop is safe.
Trade disputes over bioeconomy goods split into two kinds, and only one of them is about science. Anti-dumping and countervailing actions turn on cost accounting; sanitary and phytosanitary disputes turn on evidence about risk. The second kind is where a trade forum ends up adjudicating the quality of a risk assessment, which is an unusual thing for a trade forum to do and worth understanding on its own terms.
The evidentiary test
The SPS Agreement permits a member to set whatever level of protection it chooses. What it constrains is the reasoning. Article 2.2 requires that a measure be based on scientific principles and not maintained without sufficient scientific evidence. Article 5.1 requires it to be based on a risk assessment appropriate to the circumstances. Article 5.7 provides the escape: where relevant scientific evidence is insufficient, a member may adopt a provisional measure, but must seek the additional information needed for a more objective assessment and review the measure within a reasonable period.
The case law has given these words operational content. In EC — Hormones (DS26, 1998) the Appellate Body established that a measure need not reflect majority scientific opinion — a divergent view from a qualified and respected source can support one — but that there must be a rational relationship between the measure and the risk assessment, and the assessment must address the specific risk at issue rather than risk in the abstract. Australia — Salmon (DS18) added that an assessment must evaluate the likelihood of entry and spread, not merely its possibility. Japan — Apples (DS245, 2003) applied the sufficiency standard directly: a phytosanitary measure against fire blight transmission by apple fruit was found to rest on evidence that did not support the pathway it was designed to block.
What the case law does not decide
EC — Biotech (DS291, DS292, DS293, panel report 2006) is routinely cited as the WTO’s GMO ruling, and routinely misread. The panel decided the case on procedure — undue delay in the approval procedures under Annex C, and member-state safeguard measures unsupported by risk assessments — and expressly declined to rule on whether biotech products are safe. No WTO decision has ever held a GM crop safe or unsafe. That distinction matters when the outcome is described politically, because the finding was about administration, not biology.
On the other track, EU — Biodiesel (Argentina) (DS473, 2016) shows how bioenergy policy generates disputes with no scientific component at all. The dispute concerned whether an investigating authority may disregard a producer’s own cost records because domestic soybean prices were held down by an export tax. The Appellate Body held it may not simply substitute an international price for the recorded one, so the case turned on the anti-dumping methodology, not on biodiesel.
The practical consequence is that a measure’s survival depends less on how cautious it is than on whether an assessment document exists and whether the measure follows from it. A precautionary decision taken without a written assessment is more exposed than a strict one taken with a thin but coherent assessment — and Article 5.7’s “reasonable period” has no fixed length, so a provisional measure kept indefinitely eventually becomes the defect.